Risk assessment combining pretreatment and post-treatment prognosticators. Applying an adjusted risk stratification, combining genetics/cytogenetics and level of MRD at the end of consolidation therapy, we distinguished 2 categories of patients: (1) low-risk, including F-RK and I-RK that were MRD-negative; and (2) high-risk, including U-RK, FLT3-ITD cases, and F-RK/I-RK that were MRD-positive. The first group stands for significantly longer OS (73% vs 17%), RFS (58% vs 22%), and cumulative incidence of relapse (17% vs 77%; P < .001 for all comparisons).